Bengaluru, NFAPost: Graviti Pharmaceuticals, a research-focused pharmaceutical company with a strong and growing presence in international markets, announced the launch of its operations in Karnataka with a focus on high-quality standards in its manufacturing and at the same time harping on price competitiveness in the Indian market.
The launch event, held in the presence of its sales and marketing team spread across the state of Karnataka, marks a significant step in the company’s broader strategy to scale its footprint across key Indian markets.
Speaking to TheNFAPost, Graviti Pharmaceuticals Chief Operating Officer Thilak Vangala said India, especially the state of Karnataka market, is a very strategic market for the company.
“India is a growing market for us with its humongous size of population of 1.5 billion. But we are not like other pharma companies, but focus on quality maintenance at our manufacturing facility and keeping the price competitiveness to address the mass market,” said Graviti Pharmaceuticals Chief Operating Officer Thilak Vangala.
Building on the successful completion of one year of operations in Andhra Pradesh and Telangana, Graviti Pharmaceuticals is now expanding into Karnataka as part of its next phase of growth, reinforcing its ambition to emerge as a leading, quality-driven pharmaceutical player in India.
Headquartered in Hyderabad, the company has established a robust foundation backed by its international business operations, particularly in the United States, and a strong focus on globally benchmarked quality and compliance systems.
Gravity Pharmaceuticals Business Operations General Manager Akula Krishna Kishore said the company has made its mark with its manufacturing facility is compliant with USFDA, WHO-GMP and other leading authorities, with ongoing filings in the UK and Europe.
“Graviti Pharmaceuticals is a research-focused formulation firm that produces complex generics of the highest quality, especially in areas like Cardiovascular diseases (CVDs) and Central Nervous System (CNS) medications. The expansion in Karnataka state marks another chapter in our growth journey,” said Gravity Pharmaceuticals Business Operations General Manager Akula Krishna Kishore.
Speaking to TheNFAPost, Gravity Pharmaceuticals Business Development General Manager Naresh D said the company will expand its portfolio of offerings by launching medicines in areas like gastro and urology this year.
“We have established our international presence by becoming one of the 15th leading pharma players in the US market. We want to expand our portfolio of offerings by engaging with the medical community in India, one among the largest pharma markets in the world. You can also see Gravity Pharmaceuticals’ presence in areas like respiratory care, dermatology, and gynaecology,” said Gravity Pharmaceuticals Business Development General Manager Naresh D.
Graviti’s manufacturing facility at Pashamylaram, Hyderabad, operates in alignment with USFDA standards, reflecting the company’s commitment to delivering pharmaceutical products that meet stringent global benchmarks across quality, safety, and regulatory compliance.
Under the leadership of its Managing Director, Dheeraj Gorukanti, and Chief Operating Officer, Thilak Vangala, Graviti Pharmaceuticals continues to strengthen its strategic vision and operational excellence across markets.
Graviti Pharmaceuticals Chief Operating Officer Thilak Vangala also pointed out that the company’s entry into Karnataka represents a strategic milestone in its India growth journey.
“With a strong foundation in international markets and a continued focus on quality and compliance, we are committed to scaling our presence and delivering globally aligned pharmaceutical solutions across key therapy segments,” said Graviti Pharmaceuticals Chief Operating Officer Thilak Vangala.
The launch was attended by the company’s leadership team and key stakeholders, marking the beginning of Graviti’s focused expansion in the Karnataka market.
With this expansion, Graviti Pharmaceuticals aims to further strengthen its presence across India, while continuing to build a scalable, high-quality pharmaceutical platform aligned with global standards and long-term growth ambitions.
